Advancing Clinical Understanding of MASH from Disease Biology to Therapeutic Targets

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease rooted in metabolic and inflammatory disturbances, with systemic implications that extend far beyond the liver. As resmetirom becomes the first FDA-approved pharmacologic option—and with other agents targeting weight loss, insulin resistance, and fibrosis in late-stage development—clinicians must stay current on both the underlying disease biology and the therapeutic mechanisms driving treatment innovation. This quiz series offers a practical review of the pathophysiology and treatment targets that are shaping the modern management of MASH.